Cargando…
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor si...
Autores principales: | Lu, Minya, Zhang, Li, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Si, Xiaoyan, Xu, Yingchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049502/ https://www.ncbi.nlm.nih.gov/pubmed/31970940 http://dx.doi.org/10.1111/1759-7714.13313 |
Ejemplares similares
-
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020) -
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020) -
Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019) -
Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019) -
Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
por: Duan, Lian, et al.
Publicado: (2020)